Clinical Research Directory

Adolescents and young adults with increased likelihood of HIV acquisition * AYA 15 to 24 years of age * Classified as high risk using our screening tool. * Documented HIV un-infected as per the national HIV testing algorithm. * Willing to use PrEP * Willing to provide written informed consent. * No plans to relocate permanently in the next 6 months * No suspicion of acute HIV infection: * Hepatitis B virus surface antigen (HBsAg)-negative and accepts HB vaccination * Having no medical or social condition that, in the opinion of the study investigator, would interfere with the conduct of the study or interpretation of study results. * HIV-uninfected, based on HIV test results obtained at screening and enrolment visit and just prior to randomization. All HIV test results must be obtained and must all be negative/non-reactive according to national HIV testing algorithm. Adolescents and young adults living with HIV * AYA 15-24 years' old * Willing to receive ART at participating health facilities * Have high-risk characteristics for viral load non-suppression, such as missed visits, disengagement from care, new to care, and non-suppressed viral load (VL) on the last VL testing. * Willing to provide written informed consent. * No plans to relocate permanently in the next 6 months * Having no medical or social condition that, in the opinion of the study investigator, would interfere with the conduct of the study or interpretation of study results Exclusion Criteria: Adolescents and young adults with increased likelihood of HIV acquisition * One or more reactive HIV test results at Screening or Enrollment, even if HIV infection is not confirmed. * Has a cognitive impairment that prevents understanding of study procedures and precludes informed consent. * Plan to move out of the greater study catchment area during study period. * Enrolled in another intervention study. * Already on PrEP. * Unwilling or unable to commit to using CAB LA * Ineligible to initiate CAB-LA as per the Uganda national PrEP guidelines * Hepatotoxicity and or Hepatitis B infection * Potential exposure to HIV in past 72 hours * Signs/symptoms of acute HIV infection * Current or chronic history of liver disease or known hepatic/biliary abnormalities, history of seizure disorder, clinically significant cardiovascular disease, coagulopathy, and inflammatory skin conditions, as defined in Human Subjects Protection document. (Cabotegravir IB or package insert) * Hypersensitivity to any active substances or other substances in CAB-LA * Allergic or hypersensitivity reaction(s) with previous use of CAB or other integrase inhibitor medications Adolescents and young adults living with HIV * Not able to give written informed consent. * Not receiving care in selected facilities